Vifor Builds Its Kidney Disease Focus With $80m Angion Deal
Novel Drug Targets Two Kidney Injury Conditions
Deal helps Vifor pursue goal of becoming a leader in kidney disease therapies.
You may also be interested in...
The Swiss group has delivered on its promise to secure more deals in the nephrology space by bagging the rights in Europe, Australia and New Zealand to sparsentan, which is deep into a Phase III program for focal segmental glomerulosclerosis and IgA nephropathy.
The Swiss group has posted a solid if unspectacular set of six-month results and is "working on a number of opportunities" that should close by the end of the year, according to its CFO.
Two US VCs have led a large $75m series B financing of Belgium’s AgomAb Therapeutics, which is gaining traction in developing antibodies that act on the HGF-MET pathway, potentially reversing fibrosis and allowing damaged tissues to regain function.